HSIC
stock Healthcare Medical DistributionOverall Mixed · 42%
- Fundamentals Fair
- Trajectory Steady
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bullish 5 of 5 trend signals bullishRSI 66 — firm momentum, not yet overbought.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 30
- Open
- $84.42
- +0.15%
- Close
- $83.52
- -0.91%
- Current
- $83.52
- Prev close
- $84.29
- Today
- 1.11M
- 3-mo avg
- 1.39M
Earningscalendar synced from Yahoo 20d ago
- Most recent
- May 577 days ago
- Next expected
- Aug 4in 14 days
Recent earnings dates
- May 5 77 days ago
- Feb 24 147 days ago
- Nov 4, 2025 259 days ago
- Aug 5, 2025 350 days ago
Past earnings dates come from HSIC’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 20d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), HSIC’s fundamentals read as fair overall.
At 25.2x, investors are paying up; a fair amount of future growth is already in the price.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 3.0% margin is thin; little of each revenue dollar survives as profit.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 12.3% return on equity is respectable, in the normal range.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 3.5% return on assets is reasonable for a company of this kind.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
At 1.98, the company carries a moderate, manageable amount of debt.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.38, short-term assets cover short-term bills with a little room to spare.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 4.0% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 2.1% from the prior year: steady profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 20d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $12.4B | $12.6B | $12.3B | $12.7B | $13.2B |
| Net income | $631.0M | $538.0M | $416.0M | $390.0M | $398.0M |
| Diluted EPS | $4.45 | $3.91 | $3.16 | $3.05 | $3.27 |
| Dividend / share | — | — | — | — | — |
| Total assets | $8.5B | $8.6B | $10.6B | $10.2B | $11.2B |
| Total liabilities | $3.8B | $3.9B | $5.4B | $5.4B | $6.4B |
| Shareholder equity | $3.4B | $3.4B | $3.7B | $3.4B | $3.2B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1B | $3.2B | $3.2B | $3.2B | $3.2B | $3.3B | $3.4B | $3.4B |
| Net income | $104.0M | $99.0M | $94.0M | $110.0M | $86.0M | $101.0M | $101.0M | $107.0M |
| Diluted EPS | $0.80 | $0.78 | $0.75 | $0.88 | $0.70 | $0.84 | $0.85 | $0.92 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 20d ago
- Popeck Thomas C CEO, Henry Schein Products
- South Ronald N. SVP & Chief Financial Officer
- Ettinger Michael S EVP & Chief Operating Officer
- Mlotek Mark E EVP, Chief Strategic Officer
- Murphy Kelly Ann SVP & General Counsel
- Sheehy Christine Zayac SVP, Chief Human Res. Officer
- Bergman Stanley M Director
- Daniel William K Director
Officers and board are drawn from HSIC’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 11 New 6-month low (-17% off peak)
- Jan 12 Officer or director change reported in an 8-K
- Dec 23, 2025 Officer or director change reported in an 8-K
- Nov 4, 2025 +10.8% one-day move
- Oct 13, 2025 New 6-month low (-16% off peak)
- Sep 9, 2025 Officer or director change reported in an 8-K
- Aug 5, 2025 −7.4% one-day move
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 20d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report